Illumina (ILMN) : Advisory Services Network reduced its stake in Illumina by 10.67% during the most recent quarter end. The investment management company now holds a total of 8,215 shares of Illumina which is valued at $1,515,585 after selling 981 shares in Illumina , the firm said in a disclosure report filed with the SEC on Oct 7, 2016.Illumina makes up approximately 0.29% of Advisory Services Network’s portfolio.
Other Hedge Funds, Including , Simplex Trading added ILMN to its portfolio by purchasing 4,173 company shares during the most recent quarter which is valued at $769,877. Illumina makes up approx 0.10% of Simplex Trading’s portfolio.Bnp Paribas Arbitrage Sa boosted its stake in ILMN in the latest quarter, The investment management firm added 26,144 additional shares and now holds a total of 67,242 shares of Illumina which is valued at $12,518,443. Illumina makes up approx 0.05% of Bnp Paribas Arbitrage Sa’s portfolio.Chevy Chase Trust Holdings reduced its stake in ILMN by selling 2,669 shares or 0.78% in the most recent quarter. The Hedge Fund company now holds 338,110 shares of ILMN which is valued at $62,945,939. Illumina makes up approx 0.35% of Chevy Chase Trust Holdings’s portfolio.Washington Trust Bank reduced its stake in ILMN by selling 4 shares or 17.39% in the most recent quarter. The Hedge Fund company now holds 19 shares of ILMN which is valued at $3,537.Norman Fields Gottscho Capital Management reduced its stake in ILMN by selling 389 shares or 4.84% in the most recent quarter. The Hedge Fund company now holds 7,644 shares of ILMN which is valued at $1,423,083. Illumina makes up approx 0.95% of Norman Fields Gottscho Capital Management’s portfolio.
Illumina closed down -0.44 points or -0.24% at $184.49 with 7,73,003 shares getting traded on Friday. Post opening the session at $185.82, the shares hit an intraday low of $183.6 and an intraday high of $185.99 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Illumina reported $0.71 EPS for the quarter, missing the analyst consensus estimate by $ -0.03 based on the information available during the earnings call on May 3, 2016. Analyst had a consensus of $0.74. The company had revenue of $571.80 million for the quarter, compared to analysts expectations of $580.44 million. The company’s revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.91 EPS.
Many Wall Street Analysts have commented on Illumina. Illumina was Downgraded by CL King to ” Neutral” on Aug 22, 2016. Company shares were Reiterated by Mizuho on Jul 27, 2016 to “Neutral”, Firm has raised the Price Target to $ 148 from a previous price target of $138 .
Illumina Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms reagent kits and scanning equipment. Its customers include genomic research centers academic institutions government laboratories hospitals and reference laboratories pharmaceutical biotechnology agrigenomics commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research including de novo sequencing genetic variation analysis epigenetics and targeted screening among others. It also provides products and services for other life sciences applied markets such as agrigenomics. It also offers Clarity Run Manager Clarity LIMS Silver and Clarity LIMS Gold.